LearnGlossaryMarketStocksSuperinvestorsSign in

GRCE

Grace Therapeutics, Inc.

Healthcare · $35M market cap

Verdict

We can't put a fair value on GRCE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-24.9% a year✗
Sales growth-5.2% a year✗
Free cash flow growth—?
Return on invested capital-20.3%✗

Follow GRCE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: 3 open-market purchases worth $246K. Why purchases matter

Purchases

Kohli Prashant

Chief Executive Officer · 2026-09-09

Bought

$214K

Opaleye Management Inc.

Owns 10%+ · 2026-09-09

Bought

$12K

Opaleye Management Inc.

Owns 10%+ · 2026-09-08

Bought

$20K

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works